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Summary
The genetic concept of synthetic lethality provides a framework for identifying genotype-selective anticancer agents. In
this approach, changes in cellular physiology that arise as a consequence of oncogene activation or tumor suppressor
gene loss, rather than oncoproteins themselves, are targeted to achieve tumor selectivity. Here we show that agonists of
the TRAIL death receptor DR5 potently induce apoptosis in human cells overexpressing the MYC oncogene, both in vitro
and as tumor xenografts in vivo. MYC sensitizes cells to DR5 in a p53-independent manner by upregulating DR5 cell surface
levels and stimulating autocatalytic processing of procaspase-8. These results identify a novel mechanism by which MYC
sensitizes cells to apoptosis and validate DR5 agonists as potential MYC-selective cancer therapeutics.
Introduction tumor cells to be killed preferentially over normal cells. Agents
that could exploit this hypersensitivity would achieve tumor
specificity by a mechanism distinct from directly targeting onco-The MYC proto-oncogene encodes a basic helix loop helix zip-
per (bHLHZ) domain-containing transcription factor that plays protein function, as molecularly targeted therapeutics such as
Gleevec do (Capdeville et al., 2002; Druker, 2002). Instead,a critical role in cellular proliferation (for review, see Grandori
et al., 2000). Induced rapidly upon entry into the cell cycle, MYC they would target an oncogene-dependent sensitivity. Such a
strategy represents a pharmacogenetic approach analogous toexpression is sufficient to drive quiescent cells into proliferation.
Although MYC was originally characterized as a human onco- the concept of genetic synthetic lethality (Hartwell et al., 1997),
a term that refers to nonviability resulting from the combinedgene based on translocation of its genomic locus in Burkitt’s
lymphoma, subsequent evidence indicates that aberrant MYC presence of two mutations or alleles, neither of which by itself
is sufficient to induce death. By analogy, the pharmacogeneticexpression occurs by a wide range of mechanisms in a variety
of different tumor types (Nesbit et al., 1999; Oster et al., 2002). version of this concept would refer to a drug that does not affect
wild-type cells, but induces lethality in cells carrying a specificIndeed, MYC has been proposed to be deregulated in a large
percentage of human cancers, and its overexpression frequently genetic alteration, such as a MYC translocation or amplification
(Reddy and Kaelin, 2002). Currently, a handful of attempts tocorrelates with aggressive, poorly differentiated tumors and
poor prognosis. Paradoxically, in addition to promoting prolifer- identify such genotype-specific agents have been reported, tar-
geting cells that carry alterations in cancer-associated pathwaysation, MYC is also capable of sensitizing cells to apoptotic cell
death under certain conditions (Evan et al., 1992; Pelengaris et such as receptor-tyrosine kinase/RAS signaling pathways (Fan-
tin et al., 2002; Torrance et al., 2001) and/or in the p53 oral., 2002). While the precise mechanism by which this occurs
remains unclear, this ability is believed to result from the exis- retinoblastoma (pRB) tumor suppressor pathways (Dolma et al.,
2003).tence of cellular tumor suppressor mechanisms that are “hard-
wired” to restrain the growth of cells that have acquired onco- The cytokine TRAIL (Tumor Necrosis Factor Related Apo-
ptosis Inducing Ligand, also known as APO2L) has receivedgenic mutations.
Because MYC is deregulated in many human tumors, its much attention as a potential cancer therapeutic because it is
capable of inducing apoptosis in a wide variety of tumor cellsability to sensitize cells to apoptosis could potentially provide
a therapeutic window that would allow MYC-overexpressing while sparing most normal cell types (reviewed in Ashkenazi,
S I G N I F I C A N C E
Using a series of human cells carrying defined oncogenic genetic alterations, we show that activation of the TRAIL receptor, DR5,
induces apoptotic cell death preferentially in cells overexpressing MYC, both in vitro and in vivo. We thereby demonstrate that
MYC’s well-established ability to sensitize cells to apoptosis provides a therapeutic window that can be exploited to target a
pharmacological agent’s action specifically toward MYC-overexpressing tumor cells in vivo. In addition, our results provide insight
into the long unanswered question of why many tumor cells are sensitive to DR5-mediated apoptotic signaling while most normal
cells are resistant. Since MYC overexpression occurs frequently in human cancer, DR5 agonists, which are currently undergoing
clinical development, may be effective against a wide variety of tumor types.
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2002; Ozoren and El-Deiry, 2003). While the molecular basis for DR5-specific antagonistic monoclonal antibodies (mAbs) (Lev-
erkus et al., 2003; Sprick et al., 2002) to block TRAIL-mediatedthis selectivity is unknown, TRAIL appears to play a role in
immune surveillance against cancer (Smyth et al., 2003), sug- killing (Figure 1B). The anti-DR4 mAb, HS101, failed to protect
BJ-MYC from TRAIL-induced apoptosis. In contrast, the anti-gesting that one of its physiological functions is to recognize and
eradicate tumor cells. A homotrimeric type II transmembrane DR5 mAb, HS201, strongly protected cells. Addition of both
mAbs did not result in additional protection over that providedprotein and member of the tumor necrosis factor (TNF) family
of “death ligands,” TRAIL induces apoptosis by engaging recep- by anti-DR5 alone, suggesting that TRAIL acts primarily through
the DR5 receptor, but not DR4, to induce apoptosis in BJ-MYCtors on the cell surface and activating an intracellular cascade
of cell death-inducing proteases known as caspases through cells.
Additional evidence in support of this conclusion was ob-both mitochondria-dependent and -independent pathways
(Ashkenazi, 2002). tained using independently isolated anti-DR4 and -DR5 mAbs
(named DR4-A and DR5-A, respectively). In contrast to HS101Five TRAIL receptors have been identified to date. Of these,
the Death Receptors 4 (DR4, also known as TRAIL-R1, APO2) and HS201, these mAbs act as receptor agonists and are each
capable of inducing apoptosis with similar efficiencies in TRAIL-and 5 (DR5, also known as TRAIL-R2, TRICK2, KILLER) contain
cytoplasmic death domains and can facilitate activation of the sensitive HCT116 colon carcinoma cells (D.A.K. and M.N., un-
published data). Their specificity for their cognate receptorsinitiator caspase, caspase-8, while the others, the so-called
decoy receptors DcR1, DcR2, and OPG, lack intact death do- allows the role of each receptor to be assessed independently
of the other or of any potential protective effects by decoymains (Ashkenazi, 2002; Ozoren and El-Deiry, 2003). Function-
ally inactive, these decoy receptors can compete with DR4 and receptors (D.A.K. and M.N., unpublished data; Griffith et al.,
1999; Ichikawa et al., 2001). Similar to their response to TRAIL,DR5 for binding to TRAIL and may therefore protect some cell
types from exposure to the TRAIL ligand. BJ-MYC cells were dramatically sensitized to DR5-A, whereas
BJ cells were largely resistant (Figures 1C and 1D). However,Here we show that agonists of DR5 can act as pharmacolog-
ical agents that are synthetically lethal with MYC overexpres- both control and MYC-expressing cells were completely resis-
tant to DR4-A, confirming that MYC sensitizes BJ cells to apo-sion, potently inducing apoptosis in human cells overexpressing
the MYC oncogene, both in vitro and in tumor xenografts in vivo. ptotic signaling through the DR5 receptor, but not through DR4.
The sensitivity of BJ-MYC to DR5-A was unlikely to be dueThese results identify MYC as a critical determinant of TRAIL’s
DR5-mediated tumor specificity and suggest that DR5 agonists to increased cell proliferation caused by MYC, because co-
expression of the cyclin-dependent kinase inhibitor p27KIP1 de-may be effective as MYC-selective cancer therapeutics.
creased cell cycle progression, yet did not abolish or reduce
sensitivity to DR5-A (Supplemental Figure S1 at http://www.Results
cancercell.org/cgi/content/full/5/5/501/DC1).
To determine whether the pharmacogenetic interaction be-MYC sensitizes normal human fibroblasts
to TRAIL-induced apoptosis tween DR5 agonists and MYC deregulation is a general phe-
nomenon in human cells, we tested three additional strains ofMYC’s ability to sensitize cells to apoptotic stimuli has been
well documented, particularly in rodent fibroblasts (Pelengaris primary or genetically defined cells: two primary human fetal
lung fibroblasts, IMR90 and WI38, and a nontransformed humanet al., 2002). However, some strains of normal human fibroblasts
overexpressing MYC have been reported to resist apoptosis embryonic kidney epithelial cell line, HA1E, immortalized by
expression of the telomerase catalytic subunit TERT and theunder serum starvation conditions that are sufficient to induce
cell death in rodent cells (Vafa et al., 2002). To systematically SV40 large T antigen (SV40 LT). Each of these lines behaved
similarly to BJ cells, being resistant to TRAIL ligand, DR5-A,examine MYC’s ability to sensitize nontransformed human cells
to apoptosis, we subjected BJ primary human foreskin fibro- and DR4-A in the absence of MYC overexpression (Figure 2).
However, their MYC-expressing counterparts were all highlyblasts, as well as derivative cells, BJ-MYC, carrying a retrovirally
introduced MYC oncogene, to a variety of apoptotic stimuli. Of sensitive to TRAIL and DR5-A, but not DR4-A, suggesting that
MYC-induced sensitization to DR5 signaling is a general phe-the treatments tested, which included serum starvation, DNA-
damaging chemotherapeutic drugs, ionizing radiation, and acti- nomenon occurring in human cells of both mesenchymal and
epithelial origin.vators of the TNF, FAS, and TRAIL death receptor signaling
pathways, only TRAIL was able to induce cell death selectively
in BJ-MYC, causing 90% decrease in viability, while having MYC stimulates caspase-8 autocatalytic processing
Both DR4 and DR5 are thought to transmit apoptotic signals inno effect on BJ cells infected with vector alone (Figure 1A).
DNA-damaging agents and serum starvation also resulted in a similar manner (see Figure 3A). In response to ligand binding, a
death-inducing signaling complex (DISC) composed of trimericdecreases in viable cell counts when compared to untreated
ligand, receptor, and the adaptor protein FADD rapidly recruitscells. However, these decreases were primarily due to cell cycle
the initiator caspase procaspase-8 (Peter, 2000). Proximityarrest rather than cell death, as determined by microscopic
within the DISC facilitates dimerization of procaspase-8, re-observation of nuclear morphology and Hoechst 33342 staining
sulting in activation and proteolytic self-processing (Boatright(data not shown), and were only very modestly enhanced by
et al., 2003). Active caspase-8 can, in cell types termed type IMYC overexpression (Figure 1A).
cells, directly cleave and activate downstream effector caspases
such as caspase-3 that execute the apoptotic death programTRAIL acts through the DR5 receptor to induce
apoptosis in MYC-overexpressing cells (Fulda et al., 2002; Scaffidi et al., 1998). Alternatively, in type II
cells, active caspase-8 is insufficient to directly activate effectorTo determine through which receptor(s) TRAIL acts to induce
cell death in BJ-MYC cells, we tested the ability of DR4- and caspases, but instead cleaves the pro-apoptotic Bcl-2 family
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Figure 1. MYC sensitizes normal human fibro-
blasts to TRAIL-induced cell death via the DR5
receptor
A: BJ human foreskin fibroblasts carrying either a
stably integrated retroviral MYC expression con-
struct (BJ-MYC) or empty vector (BJ-vector) were
treated overnight with various apoptosis-induc-
ing stimuli and assayed for cell viability using Cell-
Titer-Glo (Promega).
B: Effect of anti-DR4 and anti-DR5 blocking anti-
bodies HS101 and HS201 on TRAIL-induced apo-
ptosis. BJ-MYC cells were pretreated for 1 hr with
10 g/ml blocking antibody and then stimulated
overnight with 50 ng/ml TRAIL.
C: Effect of TRAIL and agonistic anti-DR4 and
anti-DR5 antibodies (DR4-A and DR5-A, respec-
tively) on BJ, BJ-MYC, and BJ-MYC  pBABE-Bcl-
xL. In all experiments, error bars indicate stan-
dard deviations (SD) of triplicate measurements.
The absence of visible error bars indicates that
the SD was smaller than the representative
symbol.
D: Photomicrographs of BJ and BJ-MYC fibro-
blasts treated with TRAIL (200 ng/ml), DR5-A
(2 g/ml), or DR4-A (2 g/ml) for 16 hr.
member Bid to its active form, tBid, which engages the mito-
chondrial, or intrinsic, cell death pathway (LeBlanc et al., 2002;
Scaffidi et al., 1998). This results in the release of pro-apoptotic
factors such as cytochrome c and SMAC/DIABLO from the
mitochondria and subsequent activation of caspase-9 and
downstream effector caspases such as caspase-3.
To explore the mechanistic basis for the synthetic lethal
interaction between DR5-A and MYC, we examined the apo-
ptotic signaling pathway in normal human fibroblasts in the
presence or absence of ectopically expressed MYC. Upon
DR5-A stimulation, vector-transduced IMR90 and WI38 fibro-
blasts showed no processing of any of the caspases examined
(Figure 3B). In contrast, MYC-expressing cells rapidly initiated
the caspase proteolytic cascade, resulting in processing of
caspase-8, -9, and -3 and Bid within 4 hr. As Bid and caspase-9
act specifically in the mitochondrial pathway, the observed
cleavage of these proteins suggests that apoptosis in these
cells involved the engagement of the mitochondrial pathway.
However, since cells lacking ectopic MYC expression did not
exhibit autocatalytic processing of the initiator caspase, cas-
pase-8, or cleavage of its substrate Bid, these results suggest
Figure 2. MYC sensitizes multiple human cell types to TRAIL-induced cell that MYC acts by relieving a barrier to apoptosis in normal cells
death via DR5
at or upstream of caspase-8 activation.
Human fetal lung fibroblasts (IMR90 and WI38) and immortalized embryonic In type II cells, activation of downstream effector caspaseskidney cells (HA1E), all carrying either MYC-expressing (open square) or
by the mitochondrial pathway can result in further cleavage andempty vector (closed square) proviruses, were treated with TRAIL, DR5-A,
or DR4-A for 16 hr at the indicated concentrations. activation of caspase-8 (Scaffidi et al., 1998), potentially creating
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Figure 3. MYC stimulates autocatalytic pro-
cessing of caspase-8
A: Schematic of the DR5 apoptotic signaling
pathway. Dotted lines represent interactions that
do not appear to play a major role in the cell
types examined in this study, but which are pres-
ent in some cell types. See text for details.
B: Immunoblots showing proteolytic processing
of the indicated apoptotic signaling compo-
nents in MYC-expressing and control fibroblasts
treated with 0.5 g/ml DR5-A for the indicated
times. Filled arrows to the right indicate unpro-
cessed forms, open arrows indicate active pro-
cessed forms.
C: Effect of MYC and Bcl-xL on effector caspase
(DEVDase) activity in BJ cells.
D: Caspase-8 processing induced by MYC and
DR5-A is mitochondria independent. Immu-
noblots showing caspase-8 and -9 processing in
BJ-MYC cells in which mitochondrial apoptotic
function was blocked by Bcl-xL.
E: The dominant-negative MYC allele, MADMYC,
blocks apoptosis induced by DR5-A, but not tBid.
The indicated amounts of MADMYC were tran-
siently transfected to repress MYC target gene
expression. Apoptosis was induced by cotrans-
fection of a tBid expression construct or by treat-
ment with 2 g/ml DR5-A antibody.
a positive feedback loop that amplifies the apoptotic signal pression of cell death, accompanied by lack of detectable cas-
pase-9 processing (Figure 3D), suggests that mitochondrial(see Figure 3A). Thus, formally, the stimulation of caspase-8
processing by MYC, rather than being due to enhancement of apoptotic signaling was almost totally abolished by Bcl-xL.
However, under these conditions, and thus in the absence of anyautocatalytic activity at the DR5 DISC, could be due to enhance-
ment of the mitochondrial pathway, as has been proposed to mitochondrial amplification loop, caspase-8 processing was still
strongly stimulated by DR5-A in BJ-MYC cells (Figure 3D). Theseoccur in rodent fibroblasts (Juin et al., 1999). To exclude this
possibility, we retrovirally introduced into BJ-MYC a cDNA en- results therefore suggest that MYC acts at the level of cas-
pase-8 activation within the DR5 DISC.coding the anti-apoptotic Bcl-2 family member Bcl-xL, which
inhibits apoptosis by negatively regulating mitochondrial mem- To obtain further evidence that enhancement of caspase-8
activity by MYC was independent of mitochondrial amplification,brane permeability, thereby preventing the release of pro-apo-
ptotic factors. Bcl-xL strongly inhibited effector caspase activity we inhibited MYC transcriptional activity using a dominant-neg-
ative version of MYC, MADMYC, comprised of the transcrip-(Figure 3C) and cell death (Figure 1C) in BJ-MYC cells, demon-
strating that apoptosis is mitochondria dependent and proceeds tional repression domain of the MYC/MAX antagonist MAD
fused to the DNA binding and dimerization domain of MYCby a type II mechanism in these cells. The near complete sup-
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(Berns et al., 1997). Ectopic expression of MADMYC via trans- BJ-MYC cells were significantly protected from DR5-A (Figure
4E), arguing that sensitivity to DR5-A induced by MYC wasfection resulted in up to 80% decreased transcription from a
cotransfected MYC-responsive luciferase reporter construct mediated at least in part by the upregulation of DR5.
Although these results indicate that DR5 upregulation plays(data not shown) and strongly reduced sensitivity to DR5-A
(Figure 3E). However, apoptosis induced by ectopic expression a vital role in MYC-induced sensitization to apoptosis, it is likely
that MYC also sensitizes by other mechanisms (Juin et al., 1999;of the processed form of Bid, tBid, was completely insensitive
to the inhibition of MYC transcriptional activity (Figure 3E). These Klefstrom et al., 2002). This contention is supported by the fact
that reducing DR5 levels using siRNA only partially protectedresults were observed using a MYC-expressing, immortalized
derivative of BJ, BJELB-MYC, as well as the epithelial cell line BJ-MYC cells from DR5-A and that BJ-MYC cells are also sus-
ceptible to FAS-induced apoptosis if additionally sensitizedHA1E-MYC, suggesting that in human cells, MYC acts upstream
of Bid processing in the DR5 death receptor pathway. by serum starvation (Supplemental Figure S4 at http://www.
cancercell.org/cgi/content/full/5/5/501/DC1). However, since
MADMYC was unable to inhibit tBid-induced apoptosis (FigureMYC upregulates the DR5 receptor
The ability of MYC to sensitize BJ cells to activation of DR5 3E), any additional mechanisms likely act upstream of tBid.
Procaspase-8 and full-length Bid lie upstream of tBid in thepreferentially over the related receptors DR4 or FAS, which
utilize similar signaling pathways, suggests that MYC activity death receptor pathway and show elevated protein levels in
MYC-expressing cells (Figure 3B; see also Fernandez et al.,might impinge upon the TRAIL signaling pathway at the level
of the DR5 receptor itself. DR5 protein was readily detectable in 2003), raising the possibility that increased expression of these
components also contributes to MYC-induced sensitization.normal human cells by immunoblotting but became upregulated
approximately 2-fold upon MYC overexpression (Figure 4A Both bid and caspase-8 contain canonical E-box motifs within
their promoter regions (Fernandez et al., 2003, and not shown)and Supplemental Figure S2 at http://www.cancercell.org/cgi/
content/full/5/5/501/DC1), an effect that could be reversed by and are activated upon induction of MYC-ER, even in the ab-
sence of de novo protein synthesis (Figure 4C), suggesting thatretroviral MADMYC expression. The increase in total DR5 pro-
tein levels resulted in increased cell surface DR5 receptor levels, they are direct transcriptional target genes of MYC (Fernandez
et al., 2003).as determined by flow cytometry on intact cells (Figure 4B). DR4,
FAS, and TNF receptor 1 (TNFR1) surface levels all remained
unaffected by MYC, demonstrating that MYC’s effect upon cell DR5 agonists specifically kill MYC-expressing
tumors in vitro and in vivosurface death receptor levels was specific to DR5.
To determine if MYC upregulates DR5 expression at the Hahn, Weinberg, and colleagues have demonstrated that a
combination of three genetic elements is sufficient to fully con-RNA level, we assayed changes in DR5 transcript levels upon
activation of an inducible MYC fusion protein, MYC-ER (Eilers vert a variety of human cell types from normalcy to malignancy.
These elements include TERT, SV40 ER (the early region of DNAet al., 1989). MYC-ER is a fusion between MYC and the estrogen
receptor ligand binding domain, which sequesters MYC in an tumor virus SV40), and an activated allele of the proto-oncogene
HRAS, HRAS-V12 (Elenbaas et al., 2001; Hahn et al., 1999).inactive cytoplasmic complex unless stimulated with estrogens.
Addition of the estrogen analog 4-hydroxytamoxifen (OHT) to SV40 ER encodes two proteins: one, SV40 LT, disrupts the
cell’s two principal tumor suppressor pathways, the p53 andBJ cells carrying a retrovirally encoded MYC-ER (BJ-MYCER
cells) sensitized them to DR5-induced apoptosis (Supplemental pRB pathways, while the other, the small t antigen, contributes
to tumorigenic conversion by interacting with protein phospha-Figure S3 at http://www.cancercell.org/cgi/content/full/5/5/
501/DC1) and resulted in induction of DR5 transcript within 1 tase 2A (Hahn et al., 2002).
To determine if MYC activation is able to confer sensitivity tohr of OHT addition, as determined by semiquantitative RT-PCR
(Figure 4C), demonstrating that MYC induces DR5 at the RNA DR5 signaling in the context of a tumorigenic cell, we examined
human BJ fibroblasts and HA1E embryonic kidney epithelialtranscript level. Addition of OHT in BJ cells lacking MYC-ER
did not result in DR5 induction. cells that had been systematically transformed from normalcy
to malignancy by the addition of these genetic elements. TheTo determine whether MYC directly induces DR5 transcrip-
tion, we activated MYC-ER in the presence of the protein synthe- fully transformed versions of each cell type by these elements
(named BJELR and HA1ER, respectively) were largely insensi-sis inhibitor cycloheximide (CHX). Whereas CHX did not prevent
induction of the well-characterized direct MYC target gene tive to TRAIL and DR5-A (Figure 5A). However, upon introduc-
tion of an HA epitope-tagged MYC allele, MYCHA, these cellscyclin D2 (Bouchard et al., 1999), it completely prevented DR5
induction by MYC-ER (Figure 4C), suggesting that activation of became strongly sensitized. These results demonstrate that
within the cellular context of a transformed cell, as in normalDR5 by MYC occurs via an indirect mechanism. This conclusion
is supported by the absence of canonical CA(C/T)GTG MYC cells, MYC overexpression sensitizes to DR5-mediated apo-
ptotic signaling.binding sites (E-boxes) in the DR5 promoter (Yoshida et al.,
2001). The introduction of TERT, SV40 ER, and HRAS-V12 into
normal human cells renders them tumorigenic in immune-com-To determine the functional significance of DR5 receptor
upregulation by MYC, we manipulated DR5 receptor levels by promised mice (Elenbaas et al., 2001; Hahn et al., 1999). These
cells therefore provided us with the opportunity to test MYC’ssiRNA-mediated gene knockdown. Although in general, siRNA-
mediated gene silencing was not as effective in primary cells ability to confer sensitivity to DR5-induced apoptosis in tumors
growing in vivo, using completely genetically defined cells. Fullyas in established tumor cell lines (data not shown), we were
able to identify an siRNA directed against DR5 that was sufficient transformed BJELR cells, containing either MYCHA-expressing
retrovirus (BJELR-MYCHA cells) or vector control retrovirusto knock down DR5 receptor levels on BJ-MYC cells to levels
seen on BJ cells (Figure 4D). In the presence of DR5 siRNA, (BJELR-EGFP cells), gave rise to tumors with a latency of ap-
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Figure 4. MYC upregulates the DR5 receptor
A: Immunoblots showing upregulation of DR5 protein levels by MYC. Caspase-9 or Actin served as a loading control.
B: Flow cytometry analysis of death receptors on the surface of intact BJ (shaded area) and BJ-MYC (open area) cells. All analyses were performed using
mouse mAbs, detected with allophycocyanin-labeled goat-anti-mouse secondary antibody (Molecular Probes). DR4-A and DR5-A were used to measure
DR4 and DR5 receptor cell surface levels. Similar results were obtained using HS101 and HS201 mAbs. Other antibodies used were ZB4 (anti-FAS, Upstate),
MAB225 (anti-TNFR1, R&D Systems).
C: Semiquantitative RT-PCR analysis of transcript levels in BJ-MYCER cells in response to OHT, in the presence or absence of de novo protein synthesis. BJ
cells lacking MYC-ER are shown as controls. Typical results from multiple independent experiments and RT-PCR analyses are shown.
D: DR5 receptor levels on BJ cells (shaded area) and BJ-MYC cells transfected with siRNA against DR5 (solid line, unshaded) or control siRNA against
luciferase (dotted line, unshaded). The irrelevant mAb, MOPC21 (Sigma) was used as an IgG1 isotype control.
E: siRNA-mediated knockdown of DR5 receptor levels desensitizes BJ-MYC to DR5-A.
proximately 4 weeks, irrespective of MYC status, upon subcuta- To determine if the efficacy of DR5-A against MYC-express-
ing tumors correlated with induction of apoptosis, we assayedneous injection in immune-deficient SCID-BEIGE mice. To de-
termine the sensitivity of these tumors to DR5 signaling in vivo, caspase activity in tumors harvested from mice 8 hr after treat-
ment with a single IP injection of DR5-A. BJELR-MYCHA, butwe injected tumor-bearing mice intraperitoneally (IP) every sec-
ond day with 100 g of DR5-A, for a total of 5 treatments. Upon not BJELR-EGFP tumors, showed strongly increased effector
caspase activity in response to DR5-A (Figure 5E). This depen-completion of the treatments, 100% (8/8) of BJELR-MYCHA
tumors had responded to DR5-A treatment, showing a net re- dence upon both MYC and DR5-A for induction of caspase
activity could also be observed in tumors derived from the tu-duction in tumor volume (p  0.006, Figures 5B and 5C). 50%
(4/8) of these were no longer detectable after treatment, either morigenic kidney epithelial cell line HA1ER (Figure 5E). These
results thus demonstrate, using genetically defined cells thatvisibly or by palpation. 38% (3/8) resulted in a complete re-
sponse with no signs of relapse within 1 month of treatment differ only in their MYC status, that DR5 agonists can be used
to induce apoptosis specifically in MYC-overexpressing tumorscessation (Figure 5D). In contrast, BJELR-EGFP-derived tumors
lacking ectopic MYC did not show a statistically significant re- in vivo.
sponse to DR5-A (p  0.16), and none of the tumors showed
a net reduction in volume after treatment (0/5). Thus, despite MYC activity is required for DR5-induced apoptosis
in tumor-derived cell lineshaving no significant effect on tumor latency or growth rate,
ectopic MYC expression was highly significant in determining The above results demonstrate the pharmacogenetic relation-
ship between MYC and DR5 agonists in genetically engineeredtreatment outcome (p  0.0004).
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Figure 5. DR5 agonists specifically kill MYC-
expressing tumors in vitro and in vivo
A: Genetically defined tumor cells BJELR and
HA1ER infected with MYCHA retrovirus (open
square) or EGFP control retrovirus (closed square)
were assayed for sensitivity to TRAIL or DR5-A
in vitro.
B and C: Response of SCID-BEIGE mice bearing
BJELR-EGFP or BJELR-MYCHA-derived tumors to
DR5-A treatment. Mice were IP injected with 100
g DR5-A every other day with a total of 5 treat-
ments, beginning when tumors reached a mean
volume of 250–300 mm3. Tumor volume was mea-
sured by caliper. Complete response was de-
fined as elimination of visibly detectable and pal-
pable tumors, with no relapse within 1 month
following treatment completion. Filled triangles
indicate DR5-A injections.
D: Representative photographs of mice bearing
BJELR-MYCHA-derived tumors following 5 treat-
ments with DR5-A or vehicle control. Example in
right panel is of a mouse showing a complete
response.
E: In vivo caspase activity assays. Mice carrying
tumors derived from BJELR or HA1ER cells express-
ing MYCHA or vector control were treated with a
single DR5-A (50g) or vehicle control treatment.
Tumors were excised 8 hr post treatment, lysed,
normalized for protein concentration, and as-
sayed for caspase activity. Activities were nor-
malized to untreated control tumors. Each group
was comprised of 3 (BJELR) or 2 (HA1ER) mice.
tumor cells. To determine if a similar relationship exists in natu- HCT116, demonstrated that inhibition of DR5-induced cell death
rally arising human tumors, we introduced the dominant-nega- by MADMYC was accompanied by decreased caspase-8 pro-
tive MADMYC allele into a number of TRAIL-sensitive human cessing (Figure 6D) and effector caspase activity (Figure 6E).
tumor cell lines, including a cervical carcinoma (HeLa) and two This suggests that MYC is required at the same step in the
colorectal carcinomas (HCT116, HCT15). Each of the cell lines apoptotic cascade in tumor-derived cells as in genetically de-
expressed MYC at levels comparable to IMR90-MYC and WI38- fined tumorigenic cells, i.e., at the level of caspase-8 activation.
MYC cells (Figure 6A). In each of the tumor cell lines, MADMYC To confirm that MYC activity was required for caspase-8 auto-
protected significantly against DR5-A treatment, with cell sur- catalytic processing at the DR5 DISC, rather than for stimulation
vival being greater than 90% (Figure 6B). Similar protection of a mitochondrial feedback loop (see Figure 3A), we examined
could also be observed when MYC activity was reduced using
apoptotic signaling in a Bax/ derivative of HCT116 (Zhang et
siRNA-mediated gene knockdown (Figure 6C). Resistance was
al., 2000). The Bax deficiency incapacitates the mitochondrialunlikely to be due to decreased proliferation caused by reduced
pathway and thus dramatically inhibits induction of effector cas-MYC activity, because introduction of the cyclin-dependent ki-
pase activity (Figure 6E) and cell death (Figure 6B, center) bynase inhibitor p16INK4a, which caused equal or more severe de-
DR5-A in these cells. Even in the absence of mitochondrialcreases in proliferation (Supplemental Figure S5 at http://
signaling, DR5-A strongly stimulated caspase-8 processing,www.cancercell.org/cgi/content/full/5/5/501/DC1), did not re-
which could be impaired by MADMYC (Figure 6D). Thus, in cellsduce sensitivity to DR5-A (Figure 6B). MYC activity is thus critical
derived from naturally arising tumors, as in genetically definedfor sensitivity to DR5-induced apoptotic signaling in a variety
cells, MYC activity is critical for DR5-induced apoptosis becauseof tumor cell lines.
Further characterization of one of the cell lines tested, it is required for efficient caspase-8 activation at the DR5 DISC.
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MYC-induced sensitivity to DR5 agonists
is p53 independent
DNA-damaging agents are capable of sensitizing cells to TRAIL-
induced apoptosis by upregulating DR5 in a p53-dependent
fashion (Wu et al., 1997). This suggests that under some circum-
stances, TRAIL-mediated cytotoxicity can be p53 dependent
(Wang and El-Deiry, 2003). Given that MYC upregulates DR5
levels via an indirect mechanism (Figure 4C), we sought to deter-
mine if MYC’s effects required functional p53 by utilizing a
derivative of HCT116 in which both p53 alleles have been
knocked out by homologous recombination (HCT116 p53/;
Bunz et al., 1999). HCT116 p53/ and its isogenic p53/parent
display equivalent sensitivity to DR5-A, and in each cell line,
this sensitivity is MYC dependent, as apoptosis could be sup-
pressed by overexpression of MADMYC (Figure 7A). Further-
more, surface levels of DR5 receptor were similarly downregu-
lated by MADMYC in both cell lines (Figure 7B), demonstrating
that both MYC-dependent susceptibility to DR5-induced apo-
ptosis and upregulation of DR5 receptor do not require p53
activity.
Further evidence in support of this conclusion was obtained
using a dominant-negative tumor-associated allele of p53, p53-
H175. Expression of p53-H175 was sufficient to bypass  irradi-
ation-induced cell cycle arrest (Supplemental Figure S6 at http://
www.cancercell.org/cgi/content/full/5/5/501/DC1). However, it
did not abolish DR5 receptor upregulation or sensitization to
DR5-A in IMR90 cells (Figures 7C and 7D) or in BJ and WI-38
cells (data not shown). Experiments are currently in progress
to determine the p53-independent mechanisms by which MYC
induces DR5 and sensitizes to DR5-mediated apoptosis.
Discussion
Synthetic lethal targeting of MYC
as a therapeutic strategy
Because of its potent oncogenic activity and widespread dereg-
ulation in tumors, MYC has long made a tempting target for
anticancer drug development. However, attempts to chemically
disrupt its function have met with limited success, due to the
inherent difficulty of inhibiting transcription factors with small
molecules. Here, we demonstrate and validate an alternative,
Figure 6. MYC activity is required for DR5-induced apoptosis in tumor- pharmacogenetic approach to targeting MYC based on the con-
derived cell lines
cept of synthetic lethality, showing that agonists of the death
A: Immunoblot showing MYC protein levels in normal human fibroblasts and
receptor DR5 can be used to specifically eradicate MYC-overex-naturally arising tumor cell lines. Lane 1, IMR90; 2, IMR90-MYC; 3, WI38; 4,
pressing tumors both in vitro and in vivo.WI38-MYC; 5, HeLa (cervical carcinoma); 6, HCT116 (colorectal carcinoma);
7, HCT15 (colorectal carcinoma). As a conceptual framework for cancer drug discovery, syn-
B: The dominant-negative MYC allele, MADMYC, protects multiple tumor thetic lethality has a number of attractive features, particularly
cell lines from DR5-A. Tumor cell lines were infected with control retrovirus in an era in which tumor-specific genetic alterations can be
(closed square) or pBABE-MADMYC retrovirus (open square). Open triangles
rapidly identified. First, as alluded to above, it does not requirerepresent tumor cells infected with pBABE-p16INK4a retrovirus as a proliferation
that the targeted oncogene be amenable to pharmacologicalcontrol and are indistinguishable from vector control cells. Filled triangles
in middle panel represent Bax/ derivatives of HCT116. targeting. In fact, the biochemical function encoded by the onco-
C: siRNA-mediated knockdown of MYC protects HeLa cells from DR5-A. gene need not even be known, since oncoprotein function is
Immunoblot shows MYC protein levels 48 hr after siRNA transfection.
not targeted directly by the pharmacological agent. Thus, MYCD: Immunoblot showing inhibition of caspase-8 processing by MADMYC,
is targetable, despite being a member of a class of proteinseven when mitochondrial apoptotic function is disrupted by Bax deficiency.
E: Effector caspase (DEVDase) activity assays. Values were normalized to that has been particularly intractable to chemical inhibition.
untreated control cells. Second, the oncogene being targeted need not be essential
for tumor maintenance, or even causal for tumor formation. In
a number of mouse tumor models, MYC activity has been shown
to be continuously required for tumor maintenance, suggesting
that directly targeting MYC function may be an effective thera-
peutic strategy (Felsher, 2003). However, it is clear that in a
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mental system, control BJELR-EGFP cells formed tumors with
equal efficiency and latency as BJELR-MYCHA, MYC deregula-
tion was clearly not a causal prerequisite for tumor formation
and may not have been essential for tumor maintenance. Yet
MYC-expressing tumors could still be effectively targeted. Thus,
synthetic lethal targeting of MYC may be an effective strategy
against tumor types that frequently overexpress MYC but for
which no essential role for MYC in tumor formation or mainte-
nance has been established (Oster et al., 2002).
Third, pharmacogenetic synthetic lethality has the potential
to be used as an experimental approach to uncover novel or
unappreciated functions of oncogenes, in much the same man-
ner that synthetic lethal genetic interactions have been used to
elucidate biochemical or developmental pathways. Accordingly,
we have used this approach to uncover a novel mechanism by
which MYC sensitizes human cells to apoptosis, by upregulation
of the DR5 death receptor and stimulation of caspase-8 activity.
Given these advantages, it appears likely that the pharmacoge-
netic synthetic lethal strategy will provide a valuable comple-
mentary approach to more conventional oncogene targeting in
cancer drug discovery (Reddy and Kaelin, 2002).
Bypassing tumor cells’ ability to evade apoptosis
The ability to evade apoptosis is believed to be an obligatory
attribute acquired during the course of tumor progression (Ha-
nahan and Weinberg, 2000). Since MYC has been reported to
sensitize cells to many different apoptotic stimuli (Hueber et al.,
1997; Klefstrom et al., 1997; Pelengaris et al., 2002), under some
circumstances, tumors that overexpress MYC may acquire
broad resistance to apoptotic stimuli, and thus fail to respond
to DR5 agonists. This appears to be the case in small cell lung
carcinomas (Shivapurkar et al., 2002) and neuroblastomas (Teitz
et al., 2000), in which amplification of MYC or its homolog MYCN
correlates with mutation or silencing of various DISC compo-
nent-encoding genes, particularly Casp-8. Thus, in these tumor
types, MYC overexpression actually inversely correlates with
TRAIL sensitivity. This has been referred to as “the N-Myc para-
Figure 7. MYC-dependent upregulation of DR5 and sensitivity to DR5-medi- dox” (van Noesel et al., 2003), and it suggests that DR5 agonists
ated apoptosis are p53 independent alone are unlikely to be effective against all tumors with deregu-
A: p53 status does not affect the MYC-dependent sensitivity of HCT116 cells lated MYC. However, it is clear that this scenario does not apply
to DR5-A. MYC activity was manipulated by retroviral MADMYC expression. to all tumor types, since the human tumor-derived cell lines we
Retroviral p16INK4a was used to control for proliferation.
tested all displayed elevated MYC levels (Figure 6A), yet showedB: Flow cytometry analysis of DR5 receptor levels on the surface of p53/
MYC-dependent sensitivity to DR5-A (Figure 6B). In human tu-and p53/ HCT116 cells. Dark blue lines represent cells overexpressing MAD-
MYC. Light blue shaded area represents vector control cells. Thin red line mors, resistance to apoptotic stimuli is more frequently achieved
represents p16INK4-overexpressing cells and is indistinguishable from vector through inactivation of the p53 tumor suppressor pathway than
control cells.
by loss of DISC components. Given that the synthetic lethalC: Immunoblot showing that MYC-induced upregulation of DR5 occurs in
interaction between DR5-A and MYC is independent of p53IMR90 cells even in the presence of the dominant-negative p53 allele, p53-
H175. Caspase-9 levels served as a loading control. status (Figure 7), DR5 agonists may be therapeutically effective
D: MYC-induced sensitization to DR5-A in primary cells is independent of against many MYC-overexpressing tumors, including those car-
p53. IMR90-MYC cells were infected with retrovirus expressing p53-H175 and rying p53 mutations. Indeed, Epstein Barr Virus (EBV) negative
assayed for sensitivity to DR5-A. IMR90-MYC cells (open square) and IMR90-
Burkitt’s lymphoma cell lines, which are characterized by MYCMYC  p53-H175 cells (closed square) show indistinguishable sensitivities to
translocations and inactivation of the p53 pathway (LindstromDR5-A, and thus overlapping dose-response curves. Closed triangle,
IMR90  p53-H175. and Wiman, 2002), consistently express cell surface DR5 levels
and are characteristically sensitive to TRAIL-induced apoptosis
(Mouzakiti and Packham, 2003).
That DR5 agonists might be successfully used to eliminate
subset of tumors, this dependence can be lost during the course MYC-positive tumors in human patients is perhaps most strik-
of tumor progression, giving rise to tumors that no longer require ingly illustrated by the in vivo response of BJELR-MYCHA-
MYC expression for their continued growth and survival (D’Cruz derived tumors to DR5-A treatment. These tumors, which have
et al., 2001; Karlsson et al., 2003). Directly targeting MYC activity severely impaired p53 function due to inactivation by SV40 LT,
by definition contain the genetic alterations necessary to resistin such tumors would likely be ineffective. Since in our experi-
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the apoptotic stimuli encountered during tumorigenesis, at least The results presented here identify a synthetic lethal interac-
tion between DR5 agonists and MYC and elucidate the mecha-in an immune-deficient animal. Yet despite their ability to evade
nistic basis for this pharmacogenetic relationship. Importantly,apoptosis, they remain exquisitely sensitive to DR5 stimulation
they demonstrate that this interaction can be therapeutically(Figure 5). While subcutaneous xenograft tumor models have
exploited to eradicate tumors in a genotype-selective fashiontheir limitations as predictors of clinical outcome—they typically
in an animal model and thus validate DR5 agonists, as well asgrow much more rapidly than spontaneously arising human
the strategy of pharmacogenetic synthetic lethality, as feasibletumors, and thus often overestimate the ultimate clinical effects
approaches to targeting MYC in human cancer. With the ongo-of cytotoxic treatments (Sager and Lengauer, 2003)—the fact
ing development of DR5 agonists as promising anticancerthat isogenic BJELR-EGFP tumors lacking ectopic MYC grow
drugs, MYC overexpression and its associated sensitization toin vivo at the same rate as BJELR-MYCHA, yet are insensitive
apoptosis may prove to be an exploitable Achilles heel for manyto DR5-A (Figure 5C), argues that it is the pharmacogenetic and
human cancers.mechanistic interaction between DR5-A and MYC, rather than
the rapid tumor growth rate, that underlies the observed treat-
Experimental proceduresment efficacy.
Cell lines
MYC: A critical determinant of TRAIL’s Normal human fibroblasts BJ, IMR90, and WI38 and tumor cell lines HeLa,
HCT116, and HCT15 were obtained from the American Type Culture Collec-tumor specificity
tion (ATCC). Bax/ and Bax/ derivatives of HCT116 were obtained fromTumor cells can become resistant to TRAIL by a number of
Bert Vogelstein (Johns Hopkins University, Baltimore, MD). Genetically de-distinct mechanisms (Ozoren and El-Deiry, 2003). As a result,
fined immortalized or transformed cells HA1E, HA1ER, BJELB, and BJELR
comparisons between TRAIL-sensitive and -resistant tumor cell were obtained from Robert Weinberg (Whitehead Institute, Cambridge, MA).
lines have provided little insight into the long unanswered ques- Tumor cell lines were grown as recommended by ATCC. IMR90 and WI38
tion of why TRAIL sensitivity frequently arises during the course were grown in Minimum Essential Medium Eagle (ATCC) supplemented with
glutamine, penicillin/streptomycin, and 10% heat inactivated fetal bovineof tumorigenesis. Using defined genetic elements to systemati-
serum (FBS). HA1E-derived cells were grown in MEM- medium supple-cally convert human primary cells from normalcy to malignancy,
mented as above. BJ-derived cells were grown in a mixture of DMEM/we have dissociated MYC expression and sensitivity to DR5-
Medium199 at a 4:1 ratio, supplemented as above but with 15% FBS. All
mediated apoptotic signaling from the process of transforma- cells were grown at 37C in a 5% CO2 humidified incubator.
tion. We thereby demonstrate that DR5-mediated TRAIL sensi-
tivity is acquired not as a necessary physiological consequence Retroviruses
Retroviruses were produced by Lipofectamine 2000 (Invitrogen)-mediatedof transformation per se, but rather as a consequence of specific
transfection into Phoenix-A producer cells (Garry Nolan, Stanford University,aberrations, such as MYC deregulation, that are frequently asso-
Stanford, CA). Retroviral infections were performed by centrifuging targetciated with tumor formation or progression, but absent from
cells at 2700 rpm for 60–90 min at 25C with 50% retroviral supernatant
BJELR and HA1ER tumors. containing 20 mM HEPES and 8 g/ml polybrene. Typically, 2–3 rounds of
Although in genetically defined cells, MYC overexpression infection were performed to ensure infection of more than 98% of cells,
is both necessary and sufficient to confer sensitivity to DR5 as determined by flow cytometry. Retroviruses used were derivatives of
pBABEpuro, pWZLhygro, and LZRS-IRES-EGFP. pBABEpuro was used foragonists, it remains possible that in human tumors, other genetic
MYC, HRAS-V12, p53-H175, MADMYC, TERT, Bcl-xL, p27KIP1, and p16INK4adefects may also contribute to DR5 sensitivity. In fact, it has
retroviruses; pWZLhygro was used for p53-H175 retrovirus; and LZRS-IRES-been proposed that tumors are primed to respond to many
EGFP was used for MYCHA retrovirus. 2 g/ml puromycin or 200 g/ml
different apoptotic stimuli, including TRAIL signaling, by the hygromycin was used for selection.
cumulative burden of their oncogenic load (Green and Evan,
2002). In accordance with this hypothesis, it has been shown Antibodies
Antibodies used for immunoblotting were obtained from the indicated suppli-that ectopic expression of proliferation-promoting genes such
ers: MYC and Actin (Santa Cruz Biotechnology), caspase-8 and Bid (Bectonas E2F1 can also sensitize human cells to death ligands, includ-
Dickinson), DR5 (Cayman Chemical Company), caspase-9 (Cell Signaling),ing TRAIL (Phillips et al., 1999) and DR5-A (Y.W. and K.C.Q.,
and caspase-3 (R&D Systems). Anti-FAS functional antibody used was puri-
unpublished data), albeit moderately. However, E2F1 is unlikely fied IgM from clone CH11 (MBL International). DR4-A and DR5-A were
to play a major role in determining sensitivity to DR5 agonists in mouse IgG1 mAbs and will be described in greater detail elsewhere (D.A.K.
human tumors. In human cancer, E2F activity is most frequently and M.N., unpublished data). For in vitro apoptosis assays, these mAbs
were crosslinked by incubating them for 1 hr at room temperature, at a 1:3deregulated by loss of one of its upstream negative regulators,
ratio by weight with F(Ab’)2 fragment goat anti-mouse anti-Fc (Jacksonp16INK4a, and to a lesser extent pRB, yet inactivation of pRB
ImmunoResearch).function by SV40 LT failed to sensitize either HA1ER or BJELR
cells to DR5-A or TRAIL, in vitro or in vivo (Figure 5). Furthermore,
Cell death assays
re-introduction of p16INK4a into 2 tumor cell lines that lack its Three thousand to ten thousand cells per well were plated in 96-well plates
expression, HCT116 and HCT15, inhibited proliferation (Supple- in the appropriate cell culture medium, allowed to attach overnight, and
treated with various apoptotic stimuli for 16 hr. TRAIL preparations used:mental Figure S5 at http://www.cancercell.org/cgi/content/full/
Figure 1 and Supplemental Figure S4, Super Killer TRAIL (Alexis Corp),5/5/501/DC1), presumably by attenuating E2F activity, yet had
comprised of the C-terminal extracellular domain of human TRAIL (residuesno effect on sensitivity to DR5-A (Figure 6B). In striking contrast,
95–281) fused at its N terminus to a His-tag; Figures 2 and 6, TRAILreducing MYC activity severely reduced sensitivity (Figures 6B
C-terminal fragment (residues 114–281, Calbiochem). Where concentrations
and 6C), suggesting that MYC, but not E2F activity, plays a are not indicated, the following doses were used: Super Killer TRAIL (200
major and critical role in determining the sensitivity of these ng/ml), TNF (100 ng/ml), CH11 anti-FAS (2 g/ml), -irradiation (20 Gy),
cisplatin (20 M), etoposide (50 M). Cell viability assays were performedtumor cells to DR5 agonists.
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in triplicate using CellTiter-Glo (Promega) according to the manufacturer’s and Jeff Irelan, Garret Hampton, and Pedro Aza-Blanc for critical reading
of the manuscript.instructions.
Transient transfections
HA1E-MYC or BJELB-MYC (BJ-MYC cells immortalized with SV40 LT and
Received: October 29, 2003TERT) cells were transfected with pCMV-MADMYC in 384-well plates using
Revised: February 17, 2004Fugene 6 transfection reagent (Roche). Apoptosis was induced by cotrans-
Accepted: April 6, 2004fection with pCDNA3-tBid in the indicated amounts, or by adding 2 g/ml
Published: May 17, 2004crosslinked DR5-A antibody 48 hr posttransfection. Viability of the success-
fully transfected cell population was measured 64 hr posttransfection by
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